Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 47 to 55 years by 2026.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
A Phase 2 Study to evaluate the safety, tolerability, PK and PD in cystic fibrosis patients with at least 1 G542X Allele
, protocol number ELX-02 NCT04126473
This is a Phase 2 open label study to evaluate the safety, tolerability, PK and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X allelle.
16 Years and Older
Number of Visits:
Length of Participation:
Location: Alfred Hospital, Victoria
Modified Release Posaconazole in patients with cystic fibrosis
, protocol number NCT03421366
A prospective single centre observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formation, can be achieved.
18 Years and Older
Location: Multiple care centres across the US
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B)
, protocol number NCT04509050
This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
Less than 6 Years
No Mutation Requirement
No FEV1 Limit
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A)
, protocol number NCT04509050
This two part study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
0 Years to 4 Years
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in subjects with cystic fibrosis who are less than 24 months of age and have an Ivacaftor-Responsive CFTR Mutation
, protocol number NCT02725567
The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation
Maximum 24 months of Age
One copy F508del
Location: Queensland Children's Hospital & The Children's Hospital Westmead
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in subject 6 through 11 years of Age with cystic fibrosis and F/MF genotypes
, protocol number NCT04353817
This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).
6 Years through to 11 Years
Two copies of F508del
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN)
, protocol number BEGIN NCT04509050
This two-part observational study will look at the effects of CFTR modulators on growth in infants and young children with CF. These drugs are intended to help CFTR protein function closer to normal.
0 Years to 6 Years
Location: Australia & New Zealand
Study to evaluate ARO-ENaC in adults with cystic fibrosis (AROENaC-1001)
, protocol number ARO-ENaC NCT04375514
This study will evaluate the safety and tolerability of ARO-ENaC, a drug intended to thin airway surface liquid. Multiple doses of the drug will be tested in adults with cystic fibrosis to find the optimal dose.
18 Years to 55 Years
No mutation requirements
between 40% and 99%
Anti-InflammatoryNot yet recruiting
A double blind, randomized, placebo controlled, cross-over trial investigating the effect of High Amylose Maize Starch (HAMS) supplementation on fecal microbiological and inflammatory outcomes in individuals with Cystic Fibrosis and Healthy Volunteers
, protocol number ACTRN12618000283279
Cystic Fibrosis (CF) is associated with a significant increase in gut dysbiosis. Exposure to multiple courses of antibiotics as well as an inherently inflammatory gut contributes to this. We have shown that there are significant differences between the CF gut and healthy volunteers in these respects. High amylose maize starch (HAMS) is a pre-biotic food stuff produced in such a way as to encourage the production of beneficial, anti-inflammatory compounds. In laboratory culture, we have shown that HAMS increases the production of these compounds. What is not clear however is whether this laboratory data translates to a clinical benefit. This study will attempt to understand the impact of HAMS supplementation on the bacteria in the gut and the ability of the gut to make anti-inflammatory compounds, in adult patients with CF as well as in healthy control subjects.
Location: Ohio, USA
OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency (AzurRX AZ-CF2002)
, protocol number NCT04375878
This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).
30% or greater